Real-World Studies
TP53 (Investigational) Y220C Prevalence, Survival Impact, and Genomic Landscape in Ovarian Cancer
Nakajima et alJournal of gynecologic oncology

In a nationwide retrospective study of 5,144 adult patients registered in the Japanese Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database between June 2019 and May 2025, researchers evaluated the screening yield, prognostic relevance, and co-alteration landscape of the TP53 Y220C mutation in epithelial ovarian, fallopian tube, and primary peritoneal cancers. TP53 Y220C detection frequencies were assessed across histologic subtypes, and genomic co-alterations were evaluated among patients profiled with tissue-based FoundationOne CDx.
The mutation was identified in 4.2% of high-grade serous carcinomas (HGSC; 96 of 2,278), 4.3% of endometrioid carcinomas (13 of 302), 1.8% of mucinous carcinomas (4 of 227), 1.0% of low-grade serous carcinomas (1 of 96), and 0.3% of clear cell carcinomas (3 of 962). In the HGSC subgroup, overall survival calculated from C-CAT registration showed an adjusted hazard ratio of 1.19 (95% confidence interval, 0.88–1.61; p=0.271) for Y220C versus non-Y220C tumors, with additional sensitivity analyses incorporating diagnosis-time-scale delayed-entry and pre-registration treatment-timing models.
Furthermore, no individual gene or pathway-level co-alterations met the false discovery rate threshold. The study authors concluded that while neither survival outcomes nor co-alteration profiles reached statistical significance—with estimates remaining imprecise—the observed prevalence in approximately 4% of HGSC cases supports the utility of direct mutation-level detection through comprehensive genomic profiling.
Key Takeaways
- Across 5,144 screened patients, TP53 Y220C was detected in 4.2% of high-grade serous carcinomas (96/2,278), 4.3% of endometrioid carcinomas (13/302), 1.8% of mucinous carcinomas (4/227), 1.0% of low-grade serous carcinomas (1/96), and 0.3% of clear cell carcinomas (3/962).
- In high-grade serous carcinoma, TP53 Y220C was not associated with a statistically significant difference in overall survival compared with non-Y220C tumors (adjusted hazard ratio, 1.19; 95% confidence interval, 0.88–1.61; p=0.271).
- Tissue-based genomic profiling identified no pathway or individual gene co-alterations that met the false discovery rate threshold in TP53 Y220C-altered cases.
Read the original sourceJournal of gynecologic oncology
